PEspeaks

Nov 02, 2016
Policymakers, payers and pharma companies weigh strategies for rationalizing drug prices . Jill Wechsler reports.
Nov 02, 2016
FDA officials agree that large comparative clinical trials defeat the purpose of the abbreviated development program for biosimilars.
Oct 20, 2016
Leela Barham looks at NICE's latest proposals aimed at tackling the affordability challenge.
Oct 19, 2016
Cancer treatment is an increasing dilemma for health services as they try to balance patient care against budgetary constraints.
Oct 13, 2016
Pharmaceutical Executive
Answer 12 key questions to determine if your brand team is leveraging today’s winning competitive strategies and actions.
Oct 11, 2016
Pharmaceutical Executive
Highlighting the seven key trends in global pharma that drove discussion at this year's CPhI Worldwide event in Spain.
Oct 05, 2016
The UK's vote to leave the EU was the hot topic — and a source of exasperation — at last week's annual European Health Forum Gastein.
Sep 28, 2016
ISPOR's Value Assessment Stakeholder Conference showed its Special Task Force still reaching for clarification around the subject, writes Ansis Helmanis.
Sep 22, 2016
The UK is moving closer to aligning its two approaches to regulating drug pricing — the voluntary PPRS and statutory price cuts — but the headaches are likely to continue, writes Leela Barham.
Sep 07, 2016
Pharmaceutical Executive
Big pharma has become increasingly vulnerable to larger geopolitical and macroeconomic risks—a realization that has slowly creeped into their business planning, writes William Looney.
native1_300x100
lorem ipsum